Blueprint Medicines (BPMC) Revenue & Revenue Breakdown
Blueprint Medicines Revenue Highlights
Latest Revenue (Y)
$249.38M
Latest Revenue (Q)
$128.18M
Main Segment (Y)
AYVAKIT and AYVAKYT
Main Geography (Y)
UNITED STATES
Blueprint Medicines Revenue by Period
Blueprint Medicines Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $249.38M | 22.22% |
| 2022-12-31 | $204.04M | 13.30% |
| 2021-12-31 | $180.08M | -77.31% |
| 2020-12-31 | $793.74M | 1093.37% |
| 2019-12-31 | $66.51M | 49.39% |
| 2018-12-31 | $44.52M | 107.79% |
| 2017-12-31 | $21.43M | -22.85% |
| 2016-12-31 | $27.77M | 143.61% |
| 2015-12-31 | $11.40M | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Blueprint Medicines generated $249.38M in revenue during NA 2023, up 22.22% compared to the previous quarter, and up 560.14% compared to the same period a year ago.
Blueprint Medicines Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $128.18M | -7.22% |
| 2024-06-30 | $138.16M | 43.74% |
| 2024-03-31 | $96.12M | 33.57% |
| 2023-12-31 | $71.96M | 27.21% |
| 2023-09-30 | $56.57M | -1.74% |
| 2023-06-30 | $57.57M | -9.03% |
| 2023-03-31 | $63.29M | 63.19% |
| 2022-12-31 | $38.78M | -41.22% |
| 2022-09-30 | $65.98M | 80.53% |
| 2022-06-30 | $36.55M | -41.74% |
| 2022-03-31 | $62.73M | -41.38% |
| 2021-12-31 | $107.02M | 342.46% |
| 2021-09-30 | $24.19M | -11.38% |
| 2021-06-30 | $27.30M | 26.51% |
| 2021-03-31 | $21.58M | -36.74% |
| 2020-12-31 | $34.11M | -95.42% |
| 2020-09-30 | $745.12M | 8831.06% |
| 2020-06-30 | $8.34M | 35.28% |
| 2020-03-31 | $6.17M | -88.03% |
| 2019-12-31 | $51.53M | 463.88% |
| 2019-09-30 | $9.14M | 78.85% |
| 2019-06-30 | $5.11M | 600.00% |
| 2019-03-31 | $730.00K | -29.33% |
| 2018-12-31 | $1.03M | -5.66% |
| 2018-09-30 | $1.09M | -97.36% |
| 2018-06-30 | $41.44M | 4243.71% |
| 2018-03-31 | $954.00K | -41.40% |
| 2017-12-31 | $1.63M | -79.82% |
| 2017-09-30 | $8.07M | 36.98% |
| 2017-06-30 | $5.89M | 0.86% |
| 2017-03-31 | $5.84M | -24.07% |
| 2016-12-31 | $7.69M | 24.85% |
| 2016-09-30 | $6.16M | -12.81% |
| 2016-06-30 | $7.07M | 3.05% |
| 2016-03-31 | $6.86M | 47.92% |
| 2015-12-31 | $4.63M | 35.29% |
| 2015-09-30 | $3.43M | 27.50% |
| 2015-06-30 | $2.69M | 312.12% |
| 2015-03-31 | $652.00K | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | - |
Blueprint Medicines generated $128.18M in revenue during Q3 2024, up -7.22% compared to the previous quarter, and up 222.66% compared to the same period a year ago.
Blueprint Medicines Revenue Breakdown
Blueprint Medicines Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| AYVAKIT and AYVAKYT | $204.21M | $52.98M | - | - |
| Product | $204.21M | $110.99M | $22.13M | - |
| Product revenue, net | - | - | $57.69M | - |
| GAVRETO | - | - | $4.71M | - |
| Collaboration | - | - | - | $771.60M |
Blueprint Medicines's latest annual revenue breakdown by segment (product or service), as of Dec 23: AYVAKIT and AYVAKYT (50.00%), and Product (50.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $128.18M | $114.11M | $125.26M | $39.88M | $39.07M | $30.06M | $8.96M | $6.69M | $6.31M | $5.68M | $3.46M | - | - | - | - | - | - | - |
| Collaboration and License | $27.63M | $24.04M | $3.59M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | - | - | $198.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration revenue | - | - | $1.94M | $15.86M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| AYVAKIT and AYVAKYT | - | - | - | $134.97M | $34.31M | $34.93M | $30.06M | $28.63M | $28.45M | $23.84M | $20.03M | $17.27M | - | - | - | - | - | - |
| GAVRETO | - | - | - | - | $5.57M | $4.14M | - | $4.71M | - | - | - | - | - | - | - | - | - | - |
| Product revenue, net | - | - | - | - | - | - | - | $28.63M | $28.45M | $23.84M | $20.03M | $17.27M | $11.43M | - | - | - | - | - |
| Collaboration | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.62M | $27.42M | $738.81M | $2.66M | $2.71M |
Blueprint Medicines's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (82.27%), and Collaboration and License (17.73%).
Blueprint Medicines Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| UNITED STATES | $181.97M | $97.23M |
| Non-US | $22.24M | $13.77M |
Blueprint Medicines's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (89.11%), and Non-US (10.89%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 |
|---|---|---|---|
| Non-US | $15.05M | $12.65M | $9.39M |
| UNITED STATES | $113.13M | $101.46M | $83.14M |
Blueprint Medicines's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (88.26%), and Non-US (11.74%).
Blueprint Medicines Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $937.82M | $135.42M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| KRYS | Krystal Biotech | $50.70M | $83.84M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| TERN | Terns Pharmaceuticals | - | - |